Pfizer-BioNTech/COMIRNATY Vaccine Is Still Under “STUDY” Runs to be Completed at Different Intervals Between 2022-2026

” – known serious risks of myocarditis and pericarditis”

In addition to the many debates and conflicts surrounding the “approval” of the Pfizer/BioNTech/Comirnaty vaccine, there is interesting information to glean from the documents involved surrounding this controversy.

The below documents, some from the FDA’s own website, sheds further light into what seems to be a product still in its experimental/study phase. Some of the revelations are chilling, and doesn’t quite give the reassurance that an “approved” drug of this magnitude is more beneficial to us than what it is purported to be saving us from.

Screenshot of the FDA NEWS RELEASE: FDA Approves First COVID-19 Vaccine
taken on August 31, 2021
[ https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine ]
Content current as of August 23, 2021

Selected quotes in gray text boxes are from the above document:

“Specifically, in the FDA’s review for approval, the agency analyzed effectiveness data from approximately 20,000 vaccine and 20,000 placebo recipients ages 16 and older who did not have evidence of the COVID-19 virus infection within a week of receiving the second dose. The safety of Comirnaty was evaluated in approximately 22,000 people who received the vaccine and 22,000 people who received a placebo 16 years of age and older.

Based on results from the clinical trial, the vaccine was 91% effective in preventing COVID-19 disease.

More than half of the clinical trial participants were followed for safety outcomes for at least four months after the second dose. Overall, approximately 12,000 recipients have been followed for at least 6 months.

The most commonly reported side effects by those clinical trial participants who received Comirnaty were pain, redness and swelling at the injection site, fatigue, headache, muscle or joint pain, chills, and fever. The vaccine is effective in preventing COVID-19 and potentially serious outcomes including hospitalization and death.”

There are a couple of notes to take away from this document. In the above quote, it doesn’t quite specify how long the clinical trial lasted. Only that more than half of the clinical trial participants were followed for safety outcomes for 4 months after the second dose. It also states that 12,000 of the recipients were followed for at least 6 months.

Both of these numbers (4 and 6) are incredibly low quantities when taking into account pregnant women who are at the beginning of their pregnancy. The length of the clinical trial does not take into account the full 9 months needed to determine a healthy pregnancy, nor does it allow for any time to safely assess the development of the baby once born.

The data in this document also does not include differences between those of the placebo group compared to that of the “vaccine” group. In addition, if we are to only take the 12,000 participants into account, which from the wording of the document seems to allude that these are the recipients of the vaccine, that would still leave 10,000 participants unaccounted for. Just from the amount of vaccine recipients (22,000), this is 45% of their study that the data does not reflect. If we are to include the 22,000 of the participants who received the placebo, the data that was not tracked would rise to 72%.

There is also the challenge of how they determined that the vaccine actually prevented COVID. Were these recipients exposed to someone with COVID or were deliberately inoculated with the disease to see if they would get infected? Many people, myself included, have gone on for more than a year without developing COVID, or at least “COVID symptoms”. Since this data only involved a 4-6 month trial period, how many of us (vaccinated, placebo, or otherwise) can say that we have not contracted COVID during this time-frame either? Is this implying that unless you’re vaccinated, you will most likely get COVID every 4-6 months?

Another consideration to take into account are the many testimonies from well-respected and renowned doctors/scientists/virologists who are adamant in their assessment that these vaccines are unnecessary and instead further harms the immune system rather than help it.

In the same regard, those who are unvaccinated will obviously then not contract any of the possible side effects that are listed in this document as well as the many adverse events that are reported to VAERS. Which leaves one to wonder if the benefits really outweigh the risks of the COVID vaccines.

There is also the slight alteration on a different page of the FDA website that gives further clarification as to the efficacy of the COVID vaccines – which does not reflect that of what many people are influenced to believe:

Under the heading:

Q: What safety information did FDA evaluate to authorize the Pfizer-BioNTech COVID-19 Vaccine for emergency use and approve Comirnaty?

Screenshot of the Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions
taken on August 31, 2021
[ https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine-frequently-asked-questions ]
Content Current as of August 23, 2021

UPDATE on September 6, 2021: Since the FDA website decided to remove this particular section from their FAQ (as of 9/1/2021), here is a screenshot taken from the web archive showing its existence:

“While the vaccine may not prevent infection, symptoms or transmission of the virus from person to person – “

This seems to be the heart of the matter, and although it continues with, “it is effective in preventing hospitalization and death.” it is in direct conflict with what we were led to believe this whole time. Most of the mainstream media, big tech platforms, health agencies, etc. have insisted that vaccines are needed to stop transmission of the virus and to protect those around us. However, this one simple statement defies everything that people were coerced into believing.

And with the last part of the sentence concluding that it prevents hospitalization and death, which even that is debatable when looking at the scope of the situation, it leaves one to wonder why this would not be an option for people to decide to take that risk on their own account. When comparing data of young individuals as well and their extremely low risk of hospitalization and death in the COVID setting, there ARE acknowledged threats when they are injected with the vaccine.

“Additionally, the FDA conducted a rigorous evaluation of the post-authorization safety surveillance data pertaining to myocarditis and pericarditis following administration of the Pfizer-BioNTech COVID-19 Vaccine and has determined that the data demonstrate increased risks, particularly within the seven days following the second dose. The observed risk is higher among males under 40 years of age compared to females and older males. The observed risk is highest in males 12 through 17 years of age. Available data from short-term follow-up suggest that most individuals have had resolution of symptoms. However, some individuals required intensive care support. Information is not yet available about potential long-term health outcomes. The Comirnaty Prescribing Information includes a warning about these risks.”

The FDA is also acknowledging that there are higher risks involved with the Pfizer-BioNTech COVID-19 vaccine and myocarditis and pericarditis, especially in males aged 12-17, and up to age 40.

“Information is not yet available about potential long-term health outcomes.”

“In addition, the FDA is requiring the company to conduct postmarketing studies to further assess the risks of myocarditis and pericarditis following vaccination with Comirnaty. These studies will include an evaluation of long-term outcomes among individuals who develop myocarditis following vaccination with Comirnaty. In addition, although not FDA requirements, the company has committed to additional post-marketing safety studies, including conducting a pregnancy registry study to evaluate pregnancy and infant outcomes after receipt of Comirnaty during pregnancy.”

The document is also stating that the possibility of myocarditis and pericarditis is an accepted issue and will continue to be monitored after the marketing of the Comirnaty vaccine.

And in a rather blunt admission, FDA states on their own website that Comirnaty is not required to evaluate pregnancy and infant outcomes after receipt of Comirnaty during pregnancy. This would explain why the initial trial run was only monitored for 4-6 months. An outline in the BLA (Biologics License Approval) also states that Comirnaty will conduct studies on this group as we see in a later section.

BLA documents state Comirnaty vaccine studies to be conducted for the next several years

Screenshot taken from from the FDA BLA Approval on August 31, 2021
[ https://www.fda.gov/media/151710/download ]
Document dated August 23, 2021

Text below is page 5 of the FDA BLA Approval document

Your deferred pediatric studies required under section 505B(a) of the Federal Food,
Drug, and Cosmetic Act (FDCA) are required postmarketing studies. The status of
these postmarketing studies must be reported according to 21 CFR 601.28 and section
505B(a)(4)(C) of the FDCA. In addition, section 506B of the FDCA and 21 CFR 601.70
require you to report annually on the status of any postmarketing commitments or
required studies or clinical trials.

Label your annual report as an “Annual Status Report of Postmarketing Study
Requirement/Commitments”
and submit it to the FDA each year within 60 calendar
days of the anniversary date of this letter until all Requirements and Commitments
subject to the reporting requirements under section 506B of the FDCA are released or
fulfilled. These required studies are listed below:

1. Deferred pediatric Study C4591001 to evaluate the safety and effectiveness of
COMIRNATY in children 12 years through 15 years of age.

Final Protocol Submission: October 7, 2020

Study Completion: May 31, 2023

Final Report Submission: October 31, 2023

2. Deferred pediatric Study C4591007 to evaluate the safety and effectiveness of
COMIRNATY in infants and children 6 months to <12 years of age.

Final Protocol Submission: February 8, 2021

Study Completion: November 30, 2023

Final Report Submission: May 31, 2024

3. Deferred pediatric Study C4591023 to evaluate the safety and effectiveness of
COMIRNATY in infants <6 months of age.

Final Protocol Submission: January 31, 2022

Study Completion: July 31, 2024

Final Report Submission: October 31, 2024

Submit the protocols to your IND 19736, with a cross-reference letter to this BLA STN
BL 125742 explaining that these protocols were submitted to the IND. Please refer to
the PMR sequential number for each study/clinical trial and the submission number as
shown in this letter.

Submit final study reports to this BLA STN BL 125742. In order for your PREA PMRs to
be considered fulfilled, you must submit and receive approval of an efficacy or a labeling supplement. For administrative purposes, all submissions related to these required
pediatric postmarketing studies must be clearly designated as:

• Required Pediatric Assessment(s)

As the document states, the completion study of Comirnaty postmarketing (after approval) is not due until May 31, 2023 / Novermber 20, 2023 / July 31, 2024 respective of older to lower age groups. There is also another important acronym to consider, which is the IND, which stands for Investigational New Drug.

With this knowledge in hand, it’s important to note that the clinical trial run was monitored for 4-6 months after the second dose on around 55% of the recipients, while the actual “approved” drug still in its investigational/study stages is set to be monitored for 2-3 years. This is a sizeable difference in the amount of time to determine safety and efficacy, especially when considering the many events already reported to VAERS. And according to the Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions page from the FDA website:

Screenshot taken from the FDA Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions
on August 31, 2021
[ https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine-frequently-asked-questions ]
Content current as of August 23, 2021

Q: Are vaccine providers required to report side effects?
A: Providers administering Comirnaty or Pfizer-BioNTech COVID-19 Vaccine must report to the Vaccine Adverse Event Reporting System (VAERS) and to Pfizer the following information associated with the vaccine of which they become aware:
  • Vaccine administration errors whether or not associated with an adverse event
  • Serious adverse events (irrespective of attribution to vaccination)
  • Cases of Multisystem Inflammatory Syndrome
  • Cases of COVID-19 that result in hospitalization or death

Acknowledged myocarditis and pericarditis issues being studied on children

” – known serious risks of myocarditis and pericarditis”

Screenshot taken from from the FDA BLA Approval on August 31, 2021
[ https://www.fda.gov/media/151710/download ]
Document dated August 23, 2021

Text in the gray box below are from pages 6-8 of the FDA BLA Approval documents
[ https://www.fda.gov/media/151710/download ]

We have determined that an analysis of spontaneous postmarketing adverse events
reported under section 505(k)(1) of the FDCA will not be sufficient to assess known
serious risks of myocarditis and pericarditis and identify an unexpected serious risk of
subclinical myocarditis.

Furthermore, the pharmacovigilance system that FDA is required to maintain under
section 505(k)(3) of the FDCA is not sufficient to assess these serious risks.

Therefore, based on appropriate scientific data, we have determined that you are
required to conduct the following studies:

4. Study C4591009, entitled “A Non-Interventional Post-Approval Safety Study of
the Pfizer-BioNTech COVID-19 mRNA Vaccine in the United States,” to evaluate
the occurrence of myocarditis and pericarditis following administration of
COMIRNATY.

We acknowledge the timetable you submitted on August 21, 2021, which states
that you will conduct this study according to the following schedule:

Final Protocol Submission: August 31, 2021

Monitoring Report Submission: October 31, 2022

Interim Report Submission: October 31, 2023

Study Completion: June 30, 2025

Final Report Submission: October 31, 2025

5. Study C4591021, entitled “Post Conditional Approval Active Surveillance Study
Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine,” to evaluate the occurrence of myocarditis
and pericarditis following administration of COMIRNATY.

We acknowledge the timetable you submitted on August 21, 2021, which states
that you will conduct this study according to the following schedule:

Final Protocol Submission: August 11, 2021

Progress Report Submission: September 30, 2021

Interim Report 1 Submission: March 31, 2022

Interim Report 2 Submission: September 30, 2022

Interim Report 3 Submission: March 31, 2023

Interim Report 4 Submission: September 30, 2023

Interim Report 5 Submission: March 31, 2024

Study Completion: March 31, 2024

Final Report Submission: September 30, 2024

6. Study C4591021 substudy to describe the natural history of myocarditis and
pericarditis following administration of COMIRNATY.

We acknowledge the timetable you submitted on August 21, 2021, which states
that you will conduct this study according to the following schedule:

Final Protocol Submission: January 31, 2022

Study Completion: March 31, 2024

Final Report Submission: September 30, 2024

7. Study C4591036, a prospective cohort study with at least 5 years of follow-up for
potential long-term sequelae of myocarditis after vaccination (in collaboration
with Pediatric Heart Network).

We acknowledge the timetable you submitted on August 21, 2021, which states
that you will conduct this study according to the following schedule:

Final Protocol Submission: November 30, 2021

Study Completion: December 31, 2026

Final Report Submission: May 31, 2027

8. Study C4591007 substudy to prospectively assess the incidence of subclinical
myocarditis following administration of the second dose of COMIRNATY in a
subset of participants 5 through 15 years of age.

We acknowledge the timetable you submitted on August 21, 2021, which states
that you will conduct this assessment according to the following schedule:

Final Protocol Submission: September 30, 2021

Study Completion: November 30, 2023

Final Report Submission: May 31, 2024

9. Study C4591031 substudy to prospectively assess the incidence of subclinical
myocarditis following administration of a third dose of COMIRNATY in a subset of
participants 16 to 30 years of age.

We acknowledge the timetable you submitted on August 21, 2021, which states
that you will conduct this study according to the following schedule:

Final Protocol Submission: November 30, 2021

Study Completion: June 30, 2022

Final Report Submission: December 31, 2022

It is interesting that the timing to be considered for approval of these vaccines was only a 4-6 month timeframe, however, known dangers/risks, identified as “serious”, are still allowed to be approved and to be studied for 2+ years.

The document also recognizes that myocarditis and pericarditis is enough of a concern to happen after administration of the Comirnaty vaccine, since it mentions several studies just for this specific adverse event, and to continue to assess these reports.

In addition to all of the substudies to be conducted, there is a study to be initiated on a select group of participants to administer a third dose of the Comirnaty vaccine.

All of this information leads credence to the fact that even though the Comirnaty vaccine has “officially been approved” by the FDA, it is still in the investigational stages and being experimented upon on the public. And it goes without saying, but if myocarditis and pericarditis (on top of other reported side effects) are serious risks especially in children (“The observed risk is highest in males 12 through 17 years of age.”), then for this known risk to be offered to infants/toddlers defies any ethically moral boundaries and is in direct violations of the Nuremberg Code.

The next section also provides further evidence that there have been NO studies in the safety/efficacy of the Pfizer-BioNTech/Comirnaty vaccine on pregnant women.

Pregnancy/Births were not studied during the initial Pfizer-BioNTech/Comirnaty trial runs

Another snippet from the FDA Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions website page, states the following:

Screenshot taken from the FDA Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions
on August 31, 2021
[ https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine-frequently-asked-questions ]
Content current as of August 23, 2021

Q: Can pregnant or breastfeeding women receive the Comirnaty or Pfizer-BioNTech COVID-19 Vaccine?

A: While there have been no specific studies in these groups, there is no contraindication to receipt of the vaccine for pregnant or breastfeeding women. Pregnant or breastfeeding women should discuss potential benefits and risks of vaccination with their healthcare provider.

The acknowledgement above seems to indicate that the FDA and Pfizer-BioNTech/Comirnaty company have side-stepped this particular group in their vaccine studies, and have left it up to the healthcare provider to determine whether or not to administer this vaccine to pregnant women or women who are breastfeeding. This alone should be enough of a statement that there is no sufficient/professional data to analyze if the Comirnaty is safe during pregnancies/breastfeeding stages.

And if one were to consider the VAERS reporting system, in which the Pfizer-BioNTech company is required to report to, there have been numerous conditions of miscarriages/stillbirths/complications during pregnancy after administration of the COVID vaccine. While it is difficult to determine if these complications were a direct result of the vaccine, it is up to the scientific/healthcare community to investigate these cases in a thorough, unbiased and uninfluenced manner.

Another extremely alarming section of the FDA BLA Approval documents shows the following trial to be monitored in pregnant women:

Screenshot taken from from the FDA BLA Approval on August 31, 2021
[ https://www.fda.gov/media/151710/download ]
Document dated August 23, 2021

Text in the gray box below are from pages 9-10 of the FDA BLA Approval documents
[ https://www.fda.gov/media/151710/download ]
POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS
UNDER SECTION 506B

We acknowledge your written commitments as described in your letter of August 21, 2021 as outlined below:

10. Study C4591022, entitled “Pfizer-BioNTech COVID-19 Vaccine Exposure during
Pregnancy: A Non-Interventional Post-Approval Safety Study of Pregnancy and
Infant Outcomes in the Organization of Teratology Information Specialists
(OTIS)/MotherToBaby Pregnancy Registry.”

Final Protocol Submission: July 1, 2021

Study Completion: June 30, 2025

Final Report Submission: December 31, 2025

There are a couple of key takeaways in this section that are of incredible importance. One major term to focus on is the word “NON-INTERVENTIONAL“.

According to What is a Non Interventional Study?, “In general, a non interventional study (NIS) (also called a non interventional trial) is where a patient takes regular medicine, prescribed according to the label. In an NIS, the researcher sets out to exert as little influence as possible on the patient’s condition while studying a medicine’s “…effectiveness, safety and tolerability under real life conditions” (Mishra & Vora, 2010).”

The article also reiterates multiple times that “non-interventional” studies are observational studies – the researchers are not to interfere with the dosages in any way but to prescribe them exactly as listed on the label. It also seems to imply that even if severe side effects show up, they are to still carry through with the “medicinal product” in that patient as prescribed. Another insinuation that one can make is that in order to not interfere with the study, it is not recommended to prescribe treatments that may help alleviate potential side effects. The term “tolerability” is implying to keep the patient going through the side effects in order to continue to study the long-term effects of the investigational new drug.

However, with the inclusion of “real life conditions”, it doesn’t indicate whether the patient can seek out physicians to investigate what is causing the side effects in their system and engage in therapeutic treatments to alleviate these effects. If a study is to be conducted in real life conditions, then it is to be expected that patients will seek treatments on their own while the researcher is only required to observe the patient to see how the alternative treatments interact with the drug/symptoms.

The same article goes on to state that the UK/EU have different definitions of what “non-interventional” means. “Aronson (2004) states… “the term ‘non-interventional’ in the Directive doesn’t mean non-interventional (i.e. non-interference) at all; it refers to an intervention with a licensed medicinal product.”

There is controversy and conflicts in this statement as another article, Interventional or Non-Interventional? Analyzing the Differences Between Clinical Studies Using Medicines in the European Union points out:

“Although defined in DIR 2001/20/EC, non-interventional studies are outside its scope. Due to the lack of harmonized regulation, some studies designed to be non‑interventional may be considered clinical trials by EU authorities. The two blinded studies described in Table 4 (see PDF) were considered clinical trials in the EU for planning on collection of data to support the marketing authorization application of experimental IMPs, despite no IMP being given and normal clinical practice being kept during the study period. Sponsors are thus advised to consult with authorities when planning studies under these conditions and/or whenever the objectives or design may raise questions.”

Further in the article, it states the following, which again, is not reassuring considering the policies/guidelines/mandates that authorities have been engaging in in order to mandate these investigational new drugs (COVID vaccines) onto the public:

“There is no centralized submission procedure for non-interventional studies with the exception of non-interventional PASSs, imposed as an obligation by an EU competent authority.{9} Because non-interventional studies do not have harmonized legislation, some Member States require submissions to regulatory authorities, while others do not. It is therefore important that sponsors are familiar with the regulatory framework of target EU Member States, and that they consult with local competent authorities and ethics committees (ECs) when justified.”

It’s sad to have to point this out, but the quote does specify “competent” authorities. And even the inclusion of “ethics committees” is not comforting seeing as how one of the leading figures in ethics study is Christine Grady, Chief of the Department of Bioethics at the National Institutes of Health Clinical Center, and wife of Anthony Fauci – Director of the National Institute of Allergy and Infectious Diseases and Chief Medical Advisor to the president, and who is also a large spokesperson for the experimental injections.

The other takeaway from section 10 of the FDA BLA documents is the term “TERATOLOGY“.

Definition of teratology
: the study of malformations or serious deviations from the normal type in developing organisms
merriam-webster/teratology

Teratology, branch of the biological sciences dealing with the causes, development, description, and classification of congenital malformations in plants and animals and with the experimental production, in some instances, of these malformations. Congenital malformations arise from interruption in the early development of the organism. Malformations in human infants, for example, may occur because the infant’s genotype contains mutant genes or includes an abnormal number of chromosomes; they also may occur if early in pregnancy the mother has had German measles (rubella), has taken some injurious drug, or has been exposed to an injurious dosage of radiation. Experimental studies suggest similar types of factors can cause malformations in animals and plants.”
britannica/teratology

Now when you combine the terms “non-interventional” and “teratology” together, it is suggesting that the ongoing studies (that were not conducted to begin with even in a clinical trial setting, as per the FDA’s own response) on pregnant women with Comirnaty and on the developing baby, will be monitored with as little intervention as possible and is mostly to be observed for malformations/genetic defects/miscarriages/etc.

In other words, safety and efficacy were never studied in this particular group, and neither was it studied in infants. It has also not been studied for long-term analysis, as the 4-6 month trial runs proves. The current “approval” it is undergoing now is an authorized experiment on the human population that is posing incredibly unnecessary risks when considering the many effective treatments that are already available to combat respiratory illnesses. And the insistent assertiveness to push this “investigational new drug” onto babies/children who are at extremely low risk for this illness is a disastrous decision from those in an “authoritative” position and should be investigated for malfeasance and misconduct.

This is also not the first time that government agencies/health industries/etc. have conducted experiments on the public.

The Tuskegee/Syphilis experiment was initiated onto a selection of African American men between 1932-1972. The study was only stopped (allegedly) after a publication was released on Associated Press in 1972 about the immorally unethical experiments being conducted on this group:

“Of about 600 Alabama black men who originally took part in the study, 200 or so were allowed to suffer the disease and its side effects without treatment, even after penicillin was discovered as a cure for syphilis. Treatment then probably could have saved or helped many of the experiment participants, PHS officials say.”AP WAS THERE: Black men untreated in Tuskegee Syphilis Study

This study seems to echo the sentiments we see going on with the coronavirus situation, in which only one type of drug is being promoted (the COVID vaccines) while suppression of other treatments that have been proven to work (such as Ivermectin) has been denounced by the very same government/health/medical fields that have conducted these experimental studies.

A study that involved the CDC/FDA’s approval, this time on Black and Latino babies, was conducted in the early 1990’s and involved the measles vaccine:

“1990: CDC Inoculated Black and Latino Babies with an Unlicensed Measles Vaccine
A covert clinical trial by the Center for Disease Control (CDC) and Kaiser Permanente inoculated Black and Latino babies with an experimental measles vaccine without informing parents the vaccine was experimental. More than 1500 six-month old black and Hispanic babies in Los Angeles are given the deadly “experimental” measles vaccine that had never been licensed for use in the United States; a vaccine that had been tested in African and Mexican babies resulting in high death rates. The parents were never informed and they never gave their consent. The CDC harmed babies, violated federal law, and trampled on parental rights with impunity.”
1990 FDA Issued a Waiver From Consent; Covert CDC Experimental Vaccine Test on Black / Latino Babies

It’s interesting that the measles vaccine experiment identifies Kaiser Permanente specifically, because as we see in another section of the FDA BLA Approval for Comirnaty, it seems as if Kaiser Permanente makes another appearance in the role of human experimentation:

Text in the gray box below is from page 10 of the FDA BLA Approval documents
[ https://www.fda.gov/media/151710/download ]

13. Study C4591014, entitled “Pfizer-BioNTech COVID-19 BNT162b2 Vaccine
Effectiveness Study – Kaiser Permanente Southern California.”

Final Protocol Submission: March 22, 2021

Study Completion: December 31, 2022

Final Report Submission: June 30, 2023

It would seem that the approval by the FDA of these IND drugs (Pfizer-BioNTech/Comirnaty vaccine) is a way for the government/health agencies to skirt away from liability by stating that since the vaccines are no longer “experimental” by their definition, and that they are FDA “approved”, it is no longer required to gain informed consent of these drugs. In addition, as to the technicality of their terms and protocols, there are a multitude of ways to interpret their “informed consent” rules, which officials can then bend or define in any way that best reflects the use of their study/drug.

[ https://www.fda.gov/regulatory-information/search-fda-guidance-documents/informed-consent#exceptions ]

Also keeping in mind how long it was determined before the “health agencies” granted approval of the Pfizer-BioNTech/Comirnaty vaccine – (4-6 months) – it would be conclusive to state that the vaccines have NOT sufficiently been studied in young children or pregnant women (or even the rest of the age groups because of the short amount of time the clinical trial study was conducted in), and the subsequent approval of this vaccine is to continue this research on the population who is exceedingly being pressured into taking this investigational new drug.

There is also the matter of the many adverse events that have been reported since the inoculation of these injections, that have largely gone unheeded within the health/medical institutions that are endorsing this drug. Other than the widely acknowledged myocarditis and pericarditis, most common in young males, which is still being studied and allowed to persist onto the public.

So again, taking into account the collusion of the government/health/medical/research fields to conduct experiments on the public, it would be necessary to reflect upon these agencies for additional breaches upon human rights, consent, and ethical behavior.

Fair use disclaimer: Some of the links from this article are provided from different sources/sites to give the reader extra information and cite the sources, but does not necessarily mean that I endorse the contents of the site itself. Additionally, I have tried to provide links to the contents that I used from other sites as an educational and/or entertainment means only; if you feel that any information deserves further citation or request to be clarified, please let me know through the contact page.

Featured image by Ahmad Ardity from Pixabay

I'd love to hear your thoughts: